Indications and Usage
H.P. Acthar Gel (Repository Corticotropin Injection) is indicated for diagnostic testing of adrenocortical function.
H.P. Acthar Gel (Repository Corticotropin Injection) has limited therapeutic value in those conditions responsive to corticosteroid therapy; in such cases, corticosteroid therapy is considered to be the treatment of choice. H.P. Acthar Gel (Repository Corticotropin Injection) may be employed in the following disorders:
ENDOCRINE DISORDERS: Nonsuppurative thyroiditis; Hypercalcemia associated with cancer.
NERVOUS SYSTEM DISEASES: Acute exacerbations of multiple sclerosis.
RHEUMATIC DISORDERS: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Psoriatic arthritis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); Ankylosing spondylitis; Acute and subacute bursitis; Acute nonspecific tenosynovitis; Acute gouty arthritis; Post-traumatic arthritis; Synovitis of osteoarthritis; Epicondylitis.
COLLAGEN DISEASES: During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus; Systemic dermatomyositis (polymyositis); Acute rheumatic carditis.
DERMATOLOGIC DISEASES: Pemphigus; Bullous dermatitis herpetiformis; Severe erythema multiforme (Stevens-Johnson syndrome); Exfoliative dermatitis; Severe psoriasis; Severe seborrheic dermatitis; Mycosis fungoides.
ALLERGIC STATES: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis; Bronchial asthma; Contact dermatitis; Atopic dermatitis; Serum sickness.
OPHTHALMIC DISEASES: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic conjunctivitis; Keratitis; Herpes zoster ophthalmicus; Iritis and iridocyclitis; Diffuse posterior uveitis and choroiditis; Optic neuritis; Sympathetic ophthalmia; Chorioretinitis; Anterior segment inflammation; Allergic corneal marginal ulcers.
RESPIRATORY DISEASES: Symptomatic sarcoidosis; Loeffler's syndrome not manageable by other means; Berylliosis; Fulminating or disseminated pulmonary tuberculosis when used concurrently with antituberculous chemotherapy; Aspiration pneumonitis.
HEMATOLOGIC DISORDERS: Acquired (autoimmune) hemolytic anemia; Secondary thrombocytopenia in adults; Erythroblastopenia (RBC anemia); Congenital (erythroid) hypoplastic anemia.
NEOPLASTIC DISEASES: For palliative management of: Leukemias and lymphomas in adults; Acute leukemia of childhood.
EDEMATOUS STATE: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
GASTROINTESTINAL DISEASES: To tide the patient over a critical period of the disease in: Ulcerative colitis; Regional enteritis.
MISCELLANEOUS: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; Trichinosis with neurologic or myocardial involvement.